BTAI241220C1000
- 0.04
- -0.01-20.00%
BioXcel Therapeutics Newsroom
12 Health Care Stocks Moving In Friday's Pre-Market Session
Bioxcel Therapeutics Restructures Credit and Strengthens Leadership
BioXcel Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and Warrants
BioXcel Therapeutics Commences Public Offering Of Shares Of Its Common Stock And Accompanying Warrants; No Terms Disclosed
BioXcel Therapeutics Announces Proposed Public Offering
Express News | BioXcel Therapeutics- as of Nov 18, ‘431 Patent Has Been Accepted for Listing in FDA Approved Drug Products With Therapeutic Equivalence Evaluations
Mizuho Securities Maintains BioXcel Therapeutics(BTAI.US) With Hold Rating, Announces Target Price $1
BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating
Bank of America Securities Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI)
BioXcel Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.
BioXcel Therapeutics | 10-Q: Q3 2024 Earnings Report
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript Summary
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
BioXcel Therapeutics | 8-K: BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
BioXcel Therapeutics GAAP EPS of -$0.32 Beats by $0.23, Revenue of $0.21M Misses by $1.12M
Express News | BioXcel Therapeutics Q3 Operating Income USD -15.293 Million Vs. IBES Estimate USD -19.1 Million
BioXcel Therapeutics 3Q Loss/Shr 32c >BTAI
Earnings Scheduled For November 14, 2024
Here's the Major Earnings Before the Open Tomorrow
What's Next: BioXcel Therapeutics's Earnings Preview